Abstract
Despite technological progress in instrumental diagnostic investigations of the last decade, prostate cancer remains one of the most frequent malignant tumors and the second leading cause of cancer death among men. Although prostate biopsy remains the reference among all diagnosis procedures, it still exposes patients to the risk of developing complications. In this paper, the authors present a novel robotic system for prostate cancer diagnosis aimed at improving the current diagnostic procedures and reducing their undesired effects. The purpose of this work is to validate the proposed methodology by considering experimental analysis on both phantom and ex-vivo prostate tissues.
Highlights
Despite technological progress in instrumental diagnostic investigations of the last decade, prostate cancer remains one of the most frequent malignant tumors and the second leading cause of cancer death among men
Despite technological progress in instrumental diagnostic procedures, prostate biopsy still has a high risk of false negative results
BARTOLO is a project dedicated to the design of a new semi-controlled platform able to perform: (a) The prostate examination based on the digital rectal examination (DRE) procedure along the different organ areas, evaluating the prostate tissue, i.e., cancer presence and its severity; (b) A
Summary
Despite technological progress in instrumental diagnostic investigations of the last decade, prostate cancer remains one of the most frequent malignant tumors and the second leading cause of cancer death among men. Prostate biopsy remains the reference among all diagnosis procedures, it still exposes patients to the risk of developing complications. Considering its high prevalence, extreme attention should be paid to the impact of the sanitary costs arising from the diagnostic and therapeutic procedures While considering such a strong epidemiological implication, diagnostic procedures to detect this tumor have not undergone any significant developments in recent decades. The rate of complications increases in the case of patients who need a large number of tissue samples or a re-do biopsy because prostate cancer is suspected. Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
